A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Study The Efficacy And Safety Of Pembrolizumab (MK-3475) In Combination With Chemoradiotherapy (CRT) Versus CRT Alone In Participants With Muscle-Invasive Bladder Cancer (MIBC) (KEYNOTE-992)